Ricerca avanzata

Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2011 Aprile;52(2) > The Journal of Cardiovascular Surgery 2011 Aprile;52(2):225-9

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632

 

The Journal of Cardiovascular Surgery 2011 Aprile;52(2):225-9

DRUG-ELUTING TECHNOLOGIES: WHERE ARE WE 

 REVIEWS

Drug-eluting stents above the knee

Minar E.

Department of Angiology, Medical University Vienna, Vienna, Austria

There are only very few trials concerning use of drug-eluting stents (DES) in the femoropopliteal segment. While earlier trials using a sirolimus-eluting polymer-coated stent and an everolimus-eluting stent failed to demonstrate improved mid-term patency compared with a bare-metal stent, the recently presented ‑ however still unpublished – data with the Zilver PTX stent using a polymer-free paclitaxel coating are very promising. Before we can make definite conclusions and recommendations, we have to see longer-term follow-up data. A potential future improvement of local drug application for the necessary time span without the disadvantages of permanent stent implantation can be expected by the development of completely bioabsorbable DES.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina